Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Inclusion Criteria:

• Measurable or non measurable cancer that the research can assess for changes

• Not eligible or able to take existing standard therapies for cancer

• Availability of a part of a tumor for laboratory testing or willing to have a safebiopsy taken from a tumor

• Diagnosed with locally advanced, recurrent or metastatic incurable disease

• Part 1: any solid tumor (with the exception of brain cancer) that has progressed,standard therapy is no longer or has not helped the cancer, or is too toxic and forwhom a clinical trial is an option for continued treatment

• Part 1: specific advanced, metastatic tumor types will also be enrolled: colorectalcancer, small cell lung cancer, head and neck cancer, non-small cell lung cancer,pancreatic cancer, bladder cancer - some of these will have a specific gene mutationin the cancer

• Part 1: selected solid tumor cancer types (with the exception of brain cancers) thathave a specific gene mutation in the cancer

• Part 2: specific advanced, metastatic tumor types will also be enrolled: colorectalcancer, small cell lung cancer, head and neck cancer - some of these will have aspecific gene mutation in the cancer

_ Part 2: selected solid tumor cancer types (with the exception of brain cancers)that have a specific gene mutation in the cancer

• Adequate blood and urine lab tests

• Women and men of childbearing potential with adequate contraception

• Provides written informed consent

• Willing to comply with the requirements of the protocol

Exclusion Criteria:

• Inability to swallow pills

• Known history of HIV, HCV, HBV unless cured, controlled with undetectable viral load

• Active tumor in the brain

• Clinically significant liver disease

• Significant gastrointestinal diseases

• History of other cancer within past 5 years with certain exceptions for cancers thatare likely cured

• Significant cardiac disease

• Other diseases that are not well controlled that could make taking the drug unsafe

• pregnant or lactating females

• Exposure to certain anti-cancer or other drugs within a certain period before thestart of study drug